Hemostemix rolls out VesCell.Health in Florida

Executive Summary

• Hemostemix Inc. launched VesCell.Health, an educational website in Florida designed to explain the benefits of its autologous stem cell therapy, VesCell, to physicians and patients.
• The launch coincides with the enabling of Florida law SB 1768, which permits the use of VesCell for patients with life-threatening or debilitating conditions who have exhausted standard-of-care options.
• The initiative aims to make complex clinical research accessible while highlighting the company's safety and efficacy data from seven clinical trials and 11 peer-reviewed publications.

Key Details

• Product Launch: Introduction of VesCell.Health, a dedicated educational platform for Florida residents.
• Regulatory Context: Florida law SB 1768 now permits the use of VesCell under physician order and informed consent for patients with life-threatening or debilitating conditions who have exhausted standard-of-care treatment options.
• Clinical Evidence: The website serves as a repository for 11 peer-reviewed publications documenting the safety and efficacy of VesCell across seven clinical trials.
• Key Trial Data: Includes results from a Phase II double-blind randomized clinical trial in critical limb-threatening ischemia (CLTI).
• Target Conditions: The platform provides evidence-based results for angina, ischemic cardiomyopathy, non-ischemic cardiomyopathy, congestive heart failure, peripheral arterial disease, and chronic limb-threatening ischemia.
• Scientific Foundation: A recent peer-reviewed article in Cells (June 29, 2025) details how ACP-01 and NCP-01 may enhance brain-computer interface performance by reducing inflammation, fostering angiogenesis, and synaptic plasticity.
• Historical Performance: Hemostemix has completed seven clinical studies involving 318 subjects.
• CLTI Mortality Data: University of British Columbia and University of Toronto reported 0% mortality, cessation of pain, and wound healing in 83% of patients followed for up to 4.5 years, compared to a 50% five-year mortality rate in the general CLTI population.

Notable Quotes

• "Launching VesCell.Health is about giving patients and their families the information they need, in words they can understand, supported by world-class science," said Thomas Smeenk, chief executive officer of Hemostemix. "By combining plain language with peer-reviewed evidence, we are making the benefits of VesCell clear and approachable for physicians and Floridians who are searching for treatment answers and hope."